Halo Labs Secures $12 Million USD in a Series B Funding Round


(Burlingame, CA) Walk away automation, is how Halo Labs’ device is placed on the marquee.  The actual device is named, Horizon.  Currently, Horizon is designed and manufactured, so that, it has a large particle screen.  Additionally, this device’s operations are similar to a video game.  For example, writing command line code to program a liquid handler, is an automated process.  When it is in use in the laboratory, Horizon becomes, a laboratory instrument.  As a laboratory instrument, it is considered to be the industry’s first system.  Horizon; as the first system that is designed to specifically address the demand for quantitative subvisible particle analysis, does work at every stage of the biologic drug formulation process.  Being more exact about the previously said; obviously.  Recently, Halo Labs announced that, it is firmly committed to its Horizon.  Specifically, the aforementioned business revealed that, it has secured $12 million USD in a Series B funding round.  As part of the funding round, individual people invested.  The individual people are Paul McEwan and current Halo Labs employees.  The most noteworthy new investors of the aforementioned business are Research Corporation Technologies (RCT), Broad Oak Capital Partners and Bio Advance.
            Bio Advance, Broad Oak Capital Partners and Research Corporation Technologies (RCT) as the most noteworthy new investors; will be contributing funds.  The funds will be used for the following two things.  The two things are expansion and acquisition.  In reference to, expansion, the aforementioned is for the sales department.  Specifically, Halo Labs intends to use the funds to expand the worldwide sales presence, of the business.  In reference to, acquisition, the aforementioned is to expand Halo Labs’ next-generation product portfolio.  In other words; Halo Labs, is going to actively seek complementary technologies, and, businesses.  The goal of the acquisition, is to be able to, expand into the analytical particle space.
            However and returning to, Horizon, the aforementioned device is capable of true low volume high throughput subvisible particle analysis.  The previous, is how particle screening is performed.  This is done; early on as lead optimization, and, pre-formulation testing.  Therefore, hundreds of conditions can be analyzed.  This allows scientists to gain key insights, into, a drug’s stability.  This ability reduces developmental risk, and, time to market.  A proprietary background membrane imaging (B.M.I.) technology, is the power source of, Halo Labs’ Horizon.  As a result; Horizon is set apart by the fact that, it can run 200 stability test samples in less than one day.  The previously said, can be done with only 25 µL per test.  After this point, this device automatically analyzes the data.  The data results, are presented as pictures and images.
            Chad Souvignier is the Vice President of Research Corporation Technologies.  Through a press statement, Mr. Souvignier said the following.  “Horizon is crucial at every stage of biologic drug formulation.  In early stages, it can reveal SVP formation missed by other techniques such as light obscuration and flow imaging.  In later stages, it can differentiate proteins from extrinsic particles such as glass and plastic.  And given the experience of the Halo Labs management team in product development and Sales, we are eager to find other technologies that we can help bring to market.”
            To end, Halo Labs did release a press statement.  Robert Wicke is the Chief Executive Officer of Halo Labs.  Through a press statement, Mr. Wicke said the following.  “The success of Horizon, especially in the Gene Therapy field, provides confirmation that next-generation product development is critical.  There is so much more this technology can provide in a variety of markets.  One of our latest customers, the US FDA, will be using the product to help understand the risks for patients on drug product manufacturing.  This is a further indication that Horizon is the product of choice for particle analysis in the subvisible range.”  As previously stated, Halo Labs recently announced that, it is firmly committed to its Horizon.  Specifically, the aforementioned business revealed that, it has secured $12 million USD in a Series B funding round.  As part of the funding round, individual people invested.  The individual people are Paul McEwan and current Halo Labs employees.  Lastly; the most noteworthy new investors of the aforementioned business are Research Corporation Technologies (RCT), Broad Oak Capital Partners and Bio Advance.

###
Written from Press Release
Registered Writer with
PR Newswire Association, LLC
R-Berumen28
04/10/2020


Post a Comment

Previous Post Next Post